Relmada Therapeutics to Present Data at the Neuroscience Education Institute Congress

Rhea-AI Summary

Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced the presentation of data on its lead product candidate, REL-1017, at the Neuroscience Education Institute (NEI) Congress on November 5, 2021. The event will feature eight poster presentations and an interactive exhibit booth in Colorado Springs, CO. REL-1017 is being developed for treating major depressive disorder and has shown promising results in clinical trials. Registration is required for virtual and in-person participation.

CORAL GABLES, Fla., Oct. 29, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company's lead product candidate, will be presented in eight poster presentations at the Neuroscience Education Institute (NEI) Congress. The poster session will be held in-person and virtually on Friday, November 5, 2021, from 4:00 to 5:30 PM MST in Colorado Springs, CO. In addition, Relmada is hosting an interactive exhibit booth both in-person and virtually. Additional details provided below:

Participation:

• Simulcast: Registration to the NEI congress required for participation
• Virtual posters: All accepted and presented posters will be published on the NEI Virtual Poster Library; registration required
• Date: Friday, November 5, 2021
• Time: 4:00 PM to 5:30 PM MST
• Posters will be available on the virtual platform throughout the entire congress

Posters Presented: 

Title: REL-1017 (esmethadone; d-methadone) as Adjunctive Treatment in Patients with Major Depressive Disorder: A Phase 2a Double-Blind Randomized Trial.

Title: A Phase 2a Double-Blind Randomized Trial of REL-1017 (esmethadone) in Patients with Major Depressive Disorder: Analysis of Subscales from the Symptoms of Depression Questionnaire. 

Title: Case Report: REL-1017 Reduces Abnormal Clinician Administered Dissociative States Scale Scores in Patients with Major Depressive Disorder.  

Title: No Meaningful Opioid Abuse Liability of REL-1017 (esmethadone; d-methadone), a Rapid-acting Antidepressant in Clinical Development: a Human Abuse Potential Study. 

Title: REL-1017 (esmethadone; d-methadone): Assessment of Reinforcement-type Behavior, Physical Dependence, and Withdrawal in Sprague Dawley Rats. 

Title: Effect of REL-1017 (esmethadone; d-methadone) on Cholesterol, Triglycerides, PCSK9 and hs-CRP in Patients with Major Depressive Disorder. 

Title: Characterization of Esmethadone and Other NMDAR Channel Blockers on Human Heterodimeric N-methyl-D-aspartate Receptors. 

Title: REL-1017 (esmethadone; d-methadone) Did Not Produce Initial or Cumulative Neurotoxic Effects or Other Evidence of Damage to Cortical Neurons in Sprague Dawley Rats

Exhibit in-person participation:

Booth #803
Exhibit Dates & Times:

• Thursday November 4^th: 3pm – 5pm
• Friday November 5^th: 10:15am – 1:45pm and 4pm – 5:30pm
• Saturday November 6^th: 10:15am – 1:45pm and 3:30pm – 4:30pm

Online simulcast link will be available on virtual conference platform to registered virtual attendees

About REL-1017

REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the treatment of MDD in adjunctive and monotherapy Phase 3 studies. The ongoing RELIANCE Phase 3 Clinical Research Program is designed to evaluate the potential for REL-1017 as the first rapid-acting, oral, once-daily antidepressant treatment. In a Phase 2 trial, REL-1017 demonstrated rapid, robust and sustained antidepressant effects with statistically significant improvements compared to placebo in all tested measures of depression. The Phase 2 study also confirmed the favorable safety, tolerability and pharmacokinetics profile of REL-1017 observed in previously completed Phase 1 studies.

About Relmada Therapeutics, Inc. 

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada's experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada's lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment and monotherapy for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules. Learn more at www.relmada.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by Relmada or on its behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding Relmada's plans to develop REL-1017; and expectations related to trials evaluating REL-1017 and potential regulatory approval of REL-1017, including those related to feedback from the FDA. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in Relmada's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.

Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com

Media Inquiries:
FischTank PR
relmada@fischtankpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-data-at-the-neuroscience-education-institute-congress-301411913.html

SOURCE Relmada Therapeutics, Inc.

FAQ

What is the REL-1017 data presented by Relmada Therapeutics?

Relmada Therapeutics presented data on REL-1017, a treatment for major depressive disorder, at the NEI Congress on November 5, 2021.

When is the NEI Congress where REL-1017 data will be presented?

The NEI Congress will take place on November 5, 2021, from 4:00 to 5:30 PM MST.

Where can I find the REL-1017 poster presentations?

The REL-1017 poster presentations will be available on the NEI Virtual Poster Library, accessible after registration.

What are the key findings of the REL-1017 Phase 2 trial?

The REL-1017 Phase 2 trial showed rapid and sustained antidepressant effects compared to placebo, with favorable safety and tolerability.

What is the significance of the NEI Congress participation for RLMD?

Participation in the NEI Congress highlights RLMD's advancements in treatments for major depressive disorder and increases visibility in the biotech sector.